IMMUNITYBIO Trademark

Trademark Overview

On Friday, September 16, 2022, a trademark application was filed for IMMUNITYBIO with the United States Patent and Trademark Office. The USPTO has given the IMMUNITYBIO trademark a serial number of 97594955. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Thursday, October 2, 2025. This trademark is owned by NANTCELL, INC.. The IMMUNITYBIO trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, oncology, immune-oncology, immunotherapy, human diseases, animal diseases, cancer, vaccines, autoimmune diseases, and infectious diseases; product development in the fields of pharmaceuticals, oncology, immune-oncology, immunotherapy, human diseases, animal diseases, cancer, vaccines, autoimmune diseases, and infectious diseases
immunitybio

General Information

Serial Number97594955
Word MarkIMMUNITYBIO
Filing DateFriday, September 16, 2022
Status645 - FINAL REFUSAL - MAILED
Status DateThursday, October 2, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Pseudo MarkIMMUNITY BIO
Goods and ServicesMedical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, oncology, immune-oncology, immunotherapy, human diseases, animal diseases, cancer, vaccines, autoimmune diseases, and infectious diseases; product development in the fields of pharmaceuticals, oncology, immune-oncology, immunotherapy, human diseases, animal diseases, cancer, vaccines, autoimmune diseases, and infectious diseases

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, October 3, 2022
Primary Code042
First Use Anywhere DateMonday, December 21, 2020
First Use In Commerce DateMonday, December 21, 2020

Trademark Owner History

Party NameNANTCELL, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCulver City, CA 90232

Trademark Events

Event DateEvent Description
Tuesday, September 20, 2022NEW APPLICATION ENTERED
Monday, October 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 27, 2023ASSIGNED TO EXAMINER
Tuesday, June 27, 2023NON-FINAL ACTION WRITTEN
Tuesday, June 27, 2023NON-FINAL ACTION E-MAILED
Tuesday, June 27, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, September 27, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, September 27, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, December 27, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 27, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 28, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 5, 2024NON-FINAL ACTION WRITTEN
Monday, February 5, 2024NON-FINAL ACTION E-MAILED
Monday, February 5, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, May 6, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, May 6, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, August 5, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 5, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 5, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 1, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 1, 2025NON-FINAL ACTION E-MAILED
Tuesday, April 1, 2025NON-FINAL ACTION WRITTEN
Thursday, June 26, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, June 26, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, October 1, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 1, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 1, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 2, 2025FINAL REFUSAL WRITTEN
Thursday, October 2, 2025FINAL REFUSAL E-MAILED
Thursday, October 2, 2025NOTIFICATION OF FINAL REFUSAL EMAILED

Related Keywords

immunitybio diseases oncology animal human cancer infectious autoimmune vaccines immunotherapy immune